Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 95,800 shares, an increase of 102.5% from the December 31st total of 47,300 shares. Based on an average daily trading volume, of 132,000 shares, the short-interest ratio is currently 0.7 days.

Institutional Investors Weigh In On Entera Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Signature Estate & Investment Advisors LLC acquired a new position in shares of Entera Bio during the third quarter worth $90,000. Perigon Wealth Management LLC acquired a new position in shares of Entera Bio during the fourth quarter valued at about $325,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Price Performance

Shares of ENTX stock traded down $0.14 during mid-day trading on Friday, hitting $2.19. 55,144 shares of the stock traded hands, compared to its average volume of 225,967. Entera Bio has a 52-week low of $0.68 and a 52-week high of $3.35. The stock has a market cap of $78.36 million, a P/E ratio of -8.42 and a beta of 1.49. The stock’s fifty day moving average is $2.18 and its two-hundred day moving average is $1.92.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.